Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
- Q32 Bio price target lowered to $20 from $80 at Oppenheimer
- Q32 Bio Announces Mixed Results in Clinical Trials
- Q32 Bio price target lowered to $20 from $85 at Piper Sandler
- Q32 Bio downgraded to Market Perform from Outperform at Leerink
- Q32 Bio downgraded to Outperform from Strong Buy at Raymond James